MDS with ASXL1 and SETBP1 co‐mutations had a higher rate of conversion to AML and a shorter overall survival rate compared to that of ASXL mutations alone (Inoue et al., 2015). The gene discussed is ASXL1; the disease is myelodysplastic syndrome.